Dr. Eric Rowinsky’s principal expertise is in the development and registration of novel therapeutics. Dr. Rowinsky serves as a consulting CMO, CSO and/or independent advisor to a wide range of biopharmaceutical companies. Dr. Rowinsky serves as the CMO for RRD International, a Unipar company (May 2025-present), which focuses on providing strategic guidance and operational expertise in formulating strategy, as well as developing and registering novel therapeutics in cancer and other indications. Among his recent experiences in therapeutic development, Dr. Rowinsky has served as a part-time CMO of Hummingbird Biotherapeutics, a life-science company developing novel biological therapies (2021-2023), Biocity a life-science focusing on antibody drug conjugates (2022-present), and Innovative Cellular Therapeutics, a life-science company developing CART therapeutics to treat colon cancer and other solid malignancies (2022-present). From 2015 to 2025, Dr. Rowinsky served as Executive Chairman of the Board of Directors and President of Inspira, Inc. (formerly Rgenix, Inc). He also served as EVP, CMO, and Head of R&D of Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company (2011-2015). Prior to joining Stemline, Dr. Rowinsky was co-founder and CEO of Primrose Therapeutics, Inc., a start-up biotechnology company (2010-2011). From 2005 to 2010, Dr. Rowinsky was EVP and CMO of ImClone Systems Inc., where he led the FDA approval of Erbitux® (cetuximab) and advanced eight other monoclonal antibodies through clinical development. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center, including Director of the Institute of Drug Development, or IDD, and the SBC Endowed Chair for Early Drug Development at the IDD. From 1996 to 2006, Dr. Rowinsky was a Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at The Johns Hopkins University School of Medicine. Dr. Rowinsky was a longstanding National Cancer Institute principal and co-principal investigator from 1990 to 2004 and was integrally involved in pivotal clinical and preclinical investigations that led to the development of numerous cancer therapeutics, including paclitaxel, docetaxel, topotecan, irinotecan, erlotinib, gefitinib, ramucirumab, tagraxofusp and temsirolimus among others. Dr. Rowinsky presently serves on the boards of directors of the public companies Biogen Idec, Inc., Purple Bio, Inc., and Verastem Inc, as well as at a number of privately held companies. Dr. Rowinsky received a B.A. degree from New York University and an M.D. degree from Vanderbilt University School of Medicine. Dr. Rowinsky completed his residency in internal medicine at the University of California, San Diego and completed his fellowship in medical oncology at The Johns Hopkins Oncology Center.
